1:15 PM
 | 
Apr 16, 2018
 |  BC Extra  |  Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will sell its cancer business, including acute lymphoblastic leukemia (ALL) drug Oncaspar pegaspargase, to Servier (Suresnes, France) for $2.4 billion in cash.

In addition to Oncaspar, Servier will gain rights outside of the U.S. and Taiwan to pancreatic cancer drug Onivyde irinotecan, plus Shire's calaspargase pegol (Cal-PEG; SHP663), which is under FDA review to treat ALL in a first-line setting. Servier will also acquire separate early stage immuno-oncology collaborations with Precision BioSciences Inc. (Durham,...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >